文献速递免疫规划卫生政策与健康促进

为免疫功能受损者提供保护:原发性和继发性免疫缺陷患者的COVID-19预防策略

Shielding the immunocompromised: COVID-19 prevention strategies for patients with primary and secondary immunodeficiencies.
PubMed 文献 · Vaccine · 2025-02-12

本综述探讨COVID-19疫苗和单克隆抗体在原发性和继发性免疫缺陷患者中的效力,聚焦先天性免疫错误(IEI)人群,并讨论既往监管方面及将脆弱人群纳入疫苗试验的必要性,以改善患者照护并促进未来大流行中的公平健康结局。

要点

  • 免疫功能受损患者感染SARS-CoV-2后发生重症或致死性后果的风险升高。
  • 接种疫苗是COVID-19的主要防御手段,但免疫受损患者接种后的免疫应答常不理想,特异性体液应答率存在差异。
  • 未来大流行中,将脆弱人群纳入疫苗和单克隆抗体试验对制定安全有效的免疫策略至关重要。

核心结论

  • COVID-19疫苗和单克隆抗体在原发性与继发性免疫缺陷患者中的效力需全面评估,未来大流行应纳入脆弱人群以制定 tailored 指南。

研究设计与样本

  • 综述,检索范围未明确报告。

主要发现

  • 免疫功能受损患者(包括IEI、移植受者、血液恶性肿瘤及接受免疫抑制生物制剂和药物治疗者)感染SARS-CoV-2后发生重症或致死性后果的风险升高。
  • 接种疫苗是COVID-19的主要防御手段,但免疫受损患者接种后的免疫应答常不理想,特异性体液应答率存在差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The COVID-19 pandemic has significantly impacted immunocompromised patients, particularly those with inborn errors of immunity (IEI), transplant recipients, hematologic malignancies, and those undergoing treatment with immunosuppressive biologics and medications. These patients face an elevated risk of experiencing severe or even fatal consequences following SARS-CoV-2 infections. Vaccination is the primary defense against COVID-19; however, immune responses following immunization are often suboptimal in these patients, with variable specific humoral response rates. Despite the expedited regulatory approval and the widespread implementation of COVID-19 vaccines, the efficacy and safety for immunocompromised populations require thorough investigation. In future pandemics, including vulnerable populations (VPs) in vaccine and monoclonal antibody (mAb) trials is crucial to develop safe, effective immunization strategies, address gaps in vaccine efficacy and safety data, and create tailored guidelines for at-risk groups. This review provides a comprehensive examination of the efficacy of COVID-19 vaccines and mAbs in patients with primary and secondary immunodeficiency, with a specific focus on individuals with IEI, considering previous regulatory aspects and the necessity of including VPs in vaccine trials to enhance the quality of patient care and promote equitable health outcomes in future pandemics.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Olivieri G, Amodio D, Manno EC, et al. Shielding the immunocompromised: COVID-19 prevention strategies for patients with primary and secondary immunodeficiencies. Vaccine. 2025. PMID: 39946827. doi:10.1016/j.vaccine.2025.126853

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。